Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study

Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study

Abstract Mepolizumab significantly reduces the number of annual exacerbations (AEs) and the maintenance dose of systemic corticosteroids (CSs) in patients with severe eosinophilic asthma (SEA). However, there are few studies based on real life with a long-term observational period in Japan. Between...

Full description

Bibliographic Details
Main Authors: Takanori Numata, Hanae Miyagawa, Hironori Kawamoto, Masahiro Yoshida, Hirofumi Utsumi, Mitsuo Hashimoto, Shunsuke Minagawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Cogent Medicine
Subjects:
eosinophilic asthma
mepolizumab
age
body mass index
eosinophilic chronic rhinosinusitis
Online Access:http://dx.doi.org/10.1080/2331205X.2020.1776468

Internet

http://dx.doi.org/10.1080/2331205X.2020.1776468

Similar Items